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Cervical cancer screening: Safety, acceptability,  
and feasibility of a single-visit approach  
in Bulawayo, Zimbabwe
Background: Cervical cancer is the commonest cancer amongst African women, and yet preventative 
services are often inadequate.
Aim: The purpose of the study was to assess the safety, acceptability and feasibility of visual 
inspection with acetic acid and cervicography (VIAC) followed by cryotherapy or a loop electrical 
excision procedure (LEEP) at a single visit for prevention of cancer of the cervix.
Setting: The United Bulawayo Hospital, Zimbabwe.
Methods: The study was descriptive, using retrospective data extracted from electronic medical 
records of women attending the VIAC clinic. Over 24 months 4641 women visited the clinic and 
were screened for cervical cancer using VIAC. Cryotherapy or LEEP was offered immediately to 
those that screened positive. Treated women were followed up at three months and one year.
Results: The rate of positive results on VIAC testing was 10.8%. Of those who were eligible, 17.0% 
received immediate cryotherapy, 44.1% received immediate LEEP, 1.9% delayed treatment, and 
37.0% were referred to a gynaecologist. No major complications were recorded after cryotherapy or 
LEEP. Amongst those treated 99.5% expressed satisfaction with their experience. Only 3.2% of those 
treated at the clinic had a positive result on VIAC one year later. The service was shown to be feasible 
to sustain over time with the necessary consumables. There were no service-related treatment 
postponements and the clinic staff and facility were able to meet the demand for the service.
Conclusion: A single-visit approach using VIAC, followed by cryotherapy or LEEP, proved to be 
safe, acceptable and feasible in an urban African setting in Bulawayo, Zimbabwe. Outcomes a year 
later suggested that treatment had been effective.
Read online: 
Scan this QR 
code with your 
smart phone or 
mobile device 
to read online.
Dépistage du cancer du col de l’utérus: Innocuité, acceptabilité et faisabilité de l’approche à 
visite unique à Bulawayo, Zimbabwe.
Contexte: Le cancer du col de l’utérus est le plus commun parmi les femmes africaines, mais 
cependant les services de prévention sont souvent inadéquats.
Objectif: Le but de l’étude était d’évaluer l’innocuité, l’acceptabilité et la faisabilité de l’inspection 
visuelle avec de l’acide acétique et une cervico-graphie (VIAC) suivis d’une  cryothérapie ou de la 
technique d’excision électro-chirurgicale à l’anse (LEEP) en une seule visite pour la prévention du 
cancer du col de l’utérus.
Cadre: L’hôpital United Bulawayo Hospital, Zimbabwe.
Méthodes: L’étude descriptive a utilisé des données rétrospectives provenant des dossiers médicaux 
électroniques des femmes qui fréquentent les cliniques de VIAC. Sur une période de 24 mois, 4641 
femmes ont fréquenté la clinique et ont été contrôlées pour le cancer du col de l’utérus au moyen du 
VIAC. Celles dont le résultat était positif ont reçu immédiatement un traitement de Cryothérapie 
ou de LEEP. Les femmes traitées ont eu un suivi à trois mois et un an.
Résultats: Le taux de résultats positifs avec les tests de VIAC étaient de 10.8%. Parmi les personnes 
admissibles, 17.0% ont été mises immédiatement sous cryothérapie, 44.1% ont eu immédiatement 
une LEEP, 1.9% un délai de traitement, et 37.0% ont été envoyées chez un gynécologue. On n’a pas 
enregistré de complications importantes après la cryothérapie ou la LEEP. Parmi les personnes 
traitées, 99.5% étaient satisfaites de leur expérience. Seules 3.2% des femmes traitées à la clinique 
ont eu un résultat positif à la suite de la VIAC un an plus tard.  Le service s’est avéré réalisable 
pour se maintenir au fil du temps avec les produits de consommation nécessaires. Il n’y a pas eu 
de reports de traitement relatifs au service et le personnel de la clinique et l’équipement ont pu 
répondre à la demande du service.
Conclusion: L’approche d’une seule visite avec la VIAC, suivie de cryothérapie ou  LEEP, s’est 
avérée être sans danger, acceptable et faisable dans un environnement urbain africain à Bulawayo, 
Zimbabwe. Les résultats un an plus tard ont montré que le traitement avait été efficace.
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Introduction
Cervical cancer is the commonest cancer amongst African 
women and globally is exceeded only by breast cancer.1 
In sub-Saharan Africa cancer of the cervix is thought to 
account for 22% of all cancers in women, although accurate 
data are difficult to obtain in most countries.2 This cancer 
claims approximately 270 000 lives of women worldwide 
each year, and nearly 85% of those deaths occur in resource-
poor settings.1 The reasons for these high rates are because 
preventive strategies and treatment are not carried out 
well in developing countries. In resource-limited countries, 
like Zimbabwe, a shortage of skilled health workers, lack 
of political will and insufficient funds for women’s health 
activities contribute to these high rates.3
Treatment of advanced cancer is extremely difficult in 
most developing countries, whilst successful treatment 
of pre-invasive cancer should be technically possible.4 
Introduction of the Papanicolau smear has successfully 
decreased the incidence of invasive cancer and mortality in 
developed countries.4 However, even screening is difficult to 
implement in developing countries because of poverty, poor 
infrastructure, lack of financial and human resources, and 
the disempowerment of women.3
New methods for screening, such as human papillomavirus 
testing and visual inspection of the cervix with acetic acid 
(VIA),which are adaptable to limited-resource countries, 
have been investigated.3
VIA, also known as direct visual inspection, ‘involves 
examining the cervix with the naked eye, using a bright light 
source, after the application of 3% – 5% dilute acetic acid 
using a cotton swab or a spray’.3 Acetic acid is a component 
of ordinary vinegar and therefore widely available. VIA 
provides health workers with an immediate result in the 
clinic, whilst cytology requires a laboratory report. This 
approach therefore saves time, allows treatment to be given 
immediately, reduces anxiety about future test results, and 
does not require further investigations.3 Primary healthcare 
is therefore strengthened by improved access to a more 
comprehensive service.
Cervicography is taking a digital picture of the cervix 
after VIA, using a fairly ordinary camera mounted with a 
special lens.5,6,7 The photographs are viewed on a television 
or computer screen and interpreted by trained nurses or 
doctors.6,7 Cervicography magnifies the cervix so that it can 
be viewed on a large screen. It also provides a permanent 
record that can be discussed later with colleagues, can be 
shown to the client, and can be compared with previous 
pictures. Cervicography has improved the sensitivity 
and specificity of VIA. The greatest criticism of VIA has 
always been quality control: VIA with cervicography 
(VIAC) has resolved this, as there is now a visual record 
that can be discussed by colleagues and transmitted 
online.
The goal of treatment of precancerous lesions is to remove 
the lesion, and this can be accomplished by either ablation 
(cryotherapy or cautery), loop electrical excision procedure 
(LEEP), cone biopsy or hysterectomy.8,9,10 All of these 
treatment methods have a good success rate; the choice 
of treatment depends on the size or extent of the lesion, 
client acceptability, reproductive needs, cost, availability of 
equipment and expertise. Since VIAC is based on a single 
visit ‘see and treat’ approach, only treatment modalities that 
fit into this approach are discussed further: cryotherapy, 
cautery, LEEP and cone biopsy.8,9,10
Cryotherapy of the cervix is a method of destroying 
precancerous cells by cold coagulation using ice-cold gas 
and no local anesthesia.8,9 The main disadvantage is that 
there is no histological specimen available for evaluation. If 
an aceto-white lesion is visualized during VIAC, cryotherapy 
treatment can be performed following set criteria as shown in 
Figure 1.11,12,13,14
LEEP is also called large loop electro-diathermy excision 
procedure, and is performed under local anesthesia using 
2–5 mL lignocaine without adrenaline at 3-, 6-, 9-, and 
12 o’clock positions. It entails using a wire with an electrical 
current passing through it to cut and remove tissue under 
direct vision.8 The wire cuts and simultaneously coagulates. 
The transformation zone, including the lesion, is therefore 
removed. This can be used as both a diagnostic or therapeutic 
procedure.
Criteria for LEEP are as follows:8
• Aceto-white lesion covering > 75% of the transformation 
zone.
• Lesion disappearing into the os.
• Lesion contains abnormal blood vessel patterns.
• Persistent lesion after cryotherapy.
• Failure of agreement between cytology, VIAC and 
histology.
• The limits of the lesion in the cervix cannot be completely 
defined by VIAC.
The main value of the study was to investigate whether a 
single-visit approach to cervical cancer screening is acceptable 
and feasible to staff and patients, and the treatment options 
are safe. Similar projects have been undertaken in Ghana,6 
Zambia8 and Thailand.13
In Zambia the high proportion of women (67%) that accepted 
screening for cervical cancer and the high proportion of 
women completing the referral show that existing HIV 
prevention interventions provide a springboard for reaching 
women rapidly with timely, life-saving and easily adaptable 
cervical cancer prevention and treatment programmes such 
as ‘screen and treat’.9
Both the Ghanaian and the rural Thailand studies assessed 
the safety, acceptability and feasibility of cryotherapy 
performed by trained nurses. The knowledge gap to be 
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addressed was to find out if this approach is acceptable 
and safe to those accessing it in the Zimbabwean context, 
and also to evaluate if it is feasible to offer such a service 
effectively in the context of the poorly resourced health 
system. There will be a need to look at certain aspects of 
the screening process, such as follow-up care of patients 
with abnormal results, sustainability of the programme and 
whether the programme meets the screening standards set 
by the World Health Organization. The findings of the study 
will be discussed with the Ministry of Health and relevant 
policy makers, and will add knowledge required to develop 
effective health policies in Zimbabwe on an important aspect 
of women’s health.
Aim and objectives
The aim of the study was to evaluate VIAC screening and 
immediate intervention (cryotherapy or LEEP) for the 
prevention of cervical cancer amongst women attending the 
United Bulawayo Hospital in Zimbabwe. The objectives of 
the study were:
• To evaluate the safety of this approach- the proportion 
experiencing severe bleeding, shock or requiring 
hospitalisation during treatment, proportion with post-
treatment complications, and proportion returning for an 
additional visit due to problems.
• To evaluate patient satisfaction with and adherence to 
this approach – the proportion that consented at their 
single visit, proportion of treatment postponed in order 
to consult with family members, proportion attending 
follow-up appointments, proportion whose partners 
abstained from sex for four weeks after treatment by 
successfully adhering to home care instructions, and 
proportion satisfied with the screening and treatment 
service.
• To evaluate the technical feasibility of this approach – 
treatment performance rate in those who were eligible, 
and proportion with treatment postponed due to break 
down of equipment.
• To evaluate the clinical outcome – VIAC-positive rate at 
one year post-treatment at the clinic.
Research methods and design
Study design
This was a descriptive cross-sectional study using 
retrospective data from the medical records of women 
attending the VIAC clinic at United Bulawayo Hospital in 
the period 2010–2012.
Setting
The study was carried out in a VIAC clinic located at United 
Bulawayo Hospital. The VIAC clinic was incorporated 
into an already existing Family Planning clinic. The clinic 
has been functional since June 2009 and has four rooms. 
One room was for data capturing, counselling for VIAC, 
contraception and HIV services, and testing for HIV 
infection. The second room was a procedure room for VIAC 
and cryotherapy. The third room was a small theatre for 
LEEP, and the fourth room was a toilet. The clinic employed 
four midwives trained in counselling, VIAC, cryotherapy 
and family planning. Registrars, gynaecologists and junior 
doctors trained in VIAC, cryotherapy and LEEP also worked 
in this clinic.
The duration of the training course was 14–21 days. All nurses 
were expected to master VIAC and cryotherapy. Doctors 
were expected to master skills to perform VIAC, cryotherapy, 
LEEP, cautery, cone and punch biopsy, provided they worked 
in institutions where complications of those procedures can 
be dealt with adequately. The participants were trained by 
two gynaecologists and two senior registrars. Training was 
competency-based and involved observation and feedback 
on an ongoing basis.
The guideline followed by the clinic was that those who 
were HIV negative were screened for cervical cancer every 
3 years whilst those who were HIV positive were screened 
once a year.3 The recommended optimal age for screening 
was defined as 30–39 years of age, expanding to 18–65 years 
as resources permitted. Those women who received 
cryotherapy or LEEP were reviewed 4 weeks post-treatment 
and then a year later. Figure 1 shows the flow of patients in 
the VIAC clinic. Patients with cancer of the cervix were 
referred to the gynaecology clinic at the local referral 
hospital.
Study population
The study population included all women (4641) who were 
screened during the period 2010–2012. No pregnant women 
are screened at the clinic.
Data collection
Data were collected by the researcher and three research 
assistants (another doctor and two clerks) from patients’ 
electronic medical records and captured in an Excel 
spreadsheet. Data were collected to calculate the following 
variables:
• Proportion of VIAC-positive women.
• Proportion of women who were offered and accepted 
immediate post-VIAC treatment.
• Proportion of women who postponed treatment versus 
number of women who accepted it immediately.
• Proportion of women who developed complications 
during treatment.
• Proportion of women who developed complications after 
treatment (up to 6 weeks).
• Proportion of women satisfied with the service.
• Proportion of women supported by their spouses by 
abstaining from sex for 4 weeks following treatment.
• Proportion of women found with invasive cervical cancer 
on first VIAC examination.
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Suspect cancer
Aceto-white Lesion
covering >75% of the
transformation zone
Lesion disappearing
into the os
Lesion contains
abnormal
bloodvessel patterns
Perform VIAC
Negative Positive
Refer to clinical
Supervisor
Refer to UBH
gynecology clinic
Refer to
multidisciplinary
cervical cancer team
Large
lesion/Pregnancy/gynecological
abnormality 
Routine care
NoYes
Refer to clinical
supervisor
Offer cryotherapy
Counselling and 
informed
decision-making
LEEP, biopsy and/or treat larger lesion as
indicated or refer to gynaecology clinic. Manage
pregnancy and gynaecological abnormality as
indicated and postpone/ reschedule
Cervicitis
Yes No
Offer immediate
cryotherapy
3-4 month follow-up
1-year follow-up 
repeat VIAC
VIAC positive
NoYes
Lesion larger and 
same location?
Yes No
Offer immediate 
cryotherapy and
6 months follow-up
LEEP
Provide antibiotic
and reschedule
cryotherapy in
2 weeks
Repeat VIAC
Negative Positive
Cancel cryotherapy
and ask patient to
return in 3 years
Counselling and
informed decision-
making
Offer immediate
cryotherapy
3–4 months follow-up
1–year follow-up repeat
VIAC
VIAC, visual inspection with acetic acid and cervicograph; LEEP, loop electrical excision procedure.
FIGURE 1: Clinical protocol for Zimbabwe safety, acceptability and feasibility project.
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• Proportion of women returning for review after 12 
months post-treatment.
• Proportion of women found positive on VIAC upon 
follow-up after treatment.
On arrival at the clinic patients were counselled for VIAC 
and HIV testing. At the end of the VIAC procedure patients 
were presented with their results, and at the same time they 
were asked if they were satisfied with the decision they had 
made to be tested. This was recorded in their notes and used 
to calculate the proportion of women who were satisfied 
with the service.
Data analysis
Data were analysed using Excel and Epi-Info software to 
generate tables and calculate frequencies, proportions, means 
and standard deviations (SD) with 95% confidence intervals.
Ethical considerations
Permission was obtained from the Health Authority of 
United Bulawayo Hospital to conduct the research, and 
ethical approval was obtained from the Health Research 
Ethics Committee of Stellenbosch University (Ref. No. HREC 
S13/02/036). Since there was no direct contact with the 
women and only the electronic medical records were used, 
there was a waiver of informed consent.
Results
Two nurses screened 4641 women using the protocol shown 
in Figure 1 and 501 screened VIAC positive. All ages in the 
targeted range were represented; the mean age was 39 
(SD 11.3) years, as shown in Table 1. Most patients (61.2%) 
attended the clinic with one or more of the following 
complaints: lower abdominal pain, vaginal discharge, vaginal 
bleeding, backache, dyspareunia or vaginal itchiness. Only 
17.4% of women reported ever having had a Pap smear 
before. More than half (52.5%) of those screened tested HIV 
positive; some of them came to the clinic with their results 
whilst others were screened at the clinic on the VIAC day. Ten 
per cent did not know their HIV status, meaning that they had 
refused testing. The mean age of sexual debut was 18 (SD 3.7) 
years, and contraception was used by 61.9% of these women.
Overall 10.8% of the women were positive on VIAC and 
195/501 (38.9%) of those testing positive had suspected 
cancer or other problems requiring referral to a gynae cologist 
(see Figure 2).The large number of referrals to the 
gynaecologist could have been due to the fact that this was a 
new clinic and many symptomatic women were able to 
access the service for the first time. As shown in Table 2, 
85/501(17.0%) of VIAC-positive women were eligible for 
immediate treatment with cryotherapy, and of these 98.1% 
received cryotherapy during the project period. On the other 
hand, 221/501(44.1%) of VIAC-positive women were eligible 
for immediate treatment with LEEP, and of these 100% 
received LEEP during the project period.
All of the treated patients were followed up immediately 
after treatment, and only one of the women who was treated 
experienced complications. With regard to their husbands 
or partners, 97.7% of women who had received cryotherapy 
TABLE 1: Programmatic factors and cervical cancer risk factors in relation to VIAC 
positive results (N = 501).
Variable Frequency Percentage
Marital status
Single 69 13.8
Married 315 62.9
Widowed 89 17.8
Divorced 28 5.6
Previous Pap smear done
Yes 87 17.4
No 414 82.6
HIV Status
Positive 263 52.5
Negative 188 37.5
Unknown 50 10.0
Initial complaints
Vaginal bleeding 47 9.4
Vaginal discharge 41 8.2
Lower abdominal pain (LAP) 107 21.4
LAP and lower back pain 52 10.4
LAP and watery discharge 1 0.2
Lower back pain 6 1.2
Heavy menstruation 1 0.2
Post-coital bleeding 1 0.2
Watery vaginal discharge 6 1.2
LAP and vaginal bleeding 3 0.6
Dyspareunia 1 0.2
Use of contraceptives
Condoms 87 17.4
Oral contraceptives 102 20.4
Levonorgestrel implant 27 5.4
Tubal ligation 10 2.0
Depot progesterone injection 44 8.8
Intra-uterine contraceptive device 15 3.0
LAP, Lower abdominal pain.
Total women
4641
Suspected cancer
referred for treatment
195
Positive test
501
Negative test
4140
Eligible for cryotherapy
85
Received immediate
cryotherapy 84
Cryotherapy
postponed
1
VIAC
positive at
one year 
8
Eligible for
LEEP221
Received
Immediate LEEP
221
LEEP
postponed 0
VIAC, visual inspection with acetic acid and cervicograph; LEEP, loop electrical excision 
procedure.
FIGURE 2: Patient flow in visual inspection with acetic acid and cervicograph 
clinic.
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and 98.6% of those receiving LEEP were able to negotiate 
abstaining from sex in their relationships for 4 weeks. After 
treatment 97.7% were satisfied with their decision to be 
treated with cryotherapy whilst 98.6% were satisfied about 
their decision to be treated with LEEP.
One year later 96.4% of the women who had received LEEP 
came back for review and 100% of the women who had 
received cryotherapy. At one year after treatment the VIAC-
positive rate was low, at 1.2% after cryotherapy and 3.2% 
after LEEP.
Discussion
The VIAC test was positive in 10.8% of all the women 
screened, which may be higher than expected due to the 
fact that this was a new service and most women would not 
previously have had the opportunity to be screened. Of those 
who were eligible, 17.0% received immediate cryotherapy, 
44.1% immediate LEEP, 1.9% delayed treatment, and 37.0% 
were referred to a gynaecologist. No major complications 
were recorded after cryotherapy or LEEP. Amongst those 
who were treated, 99.5% expressed satisfaction with their 
experience. Only 2.6% of those who were treated at the clinic 
were VIAC-positive one year later.
This study therefore shows that VIAC followed by treatment 
with either cryotherapy or LEEP is safe, acceptable, 
feasible and effective in a poorly resourced setting such as 
Bulawayo, Zimbabwe. The study supports the viewpoint 
that this approach should be considered as an alternative 
to prevention programmes based on cytology in areas 
where technical, infrastructural, and financial barriers 
exist.5,6,7 The safety and effectiveness of VIAC, cryotherapy 
and LEEP performed by nurses and junior doctors in this 
study was also seen in studies from Zambia, Ghana, India 
andThailand.6,8,13
The need for such task shifting to nurses and junior 
doctors in our setting is important because of the lack of 
human resources for health. As part of routine quality 
assurance, aceto-white lesions one year post- cryotherapy 
or LEEP is an indication for retreatment or referral. Positive 
VIAC test rates amongst the women who returned after 
cryotherapy and LEEP were 1.2% and 3.2% respectively. 
VIAC is known to have a high negative predictive value in 
primary care settings (at least 96%), and therefore these low 
rates on follow-up suggest that cancers were successfully 
treated.15,16,17
The approach evaluated in this study was also acceptable 
to women, and there was good adherence to the 
programmatic requirements for follow-up and abstinence. 
Adherence to post-procedure instructions and follow-up 
was higher than in a similar study in Ghana, which might 
be due to the emphasis on counselling in this clinic in 
Bulawayo.6 A further study should look into the factors 
which resulted in a good follow-up rate, as this is often 
cited as a barrier to effective screening programmes in 
developing countries.17
Feasibility of sustaining and providing the service was also 
good, and even in Zimbabwe it was possible to obtain the 
gas supply for cryotherapy, as well as the consumables 
necessary for VIAC and LEEP in this urban setting. There 
were no service-related treatment postponements and 
the clinic staff and facility were able to meet the demand 
for the service. VIAC with immediate cryotherapy or 
LEEP has also been shown to be cost-effective in other 
settings.16
If screening was able to reach 70% of the target population 
over a 5–10-year period, then mortality could be reduced by 
25%.6 It is not possible to calculate an accurate population 
coverage rate from the data in this study. Future studies 
should look at how to achieve such population coverage and 
measure the impact on morbidity and mortality, as well as 
investigate the cost, sustainability and quality assurance of 
such a service.5,6,7
Conclusion
The results indicate that a single-visit approach based on 
VIAC, cryotherapy and LEEP performed by trained nurses 
and junior doctors respectively is safe and feasible in this 
low-resourced urban setting in Zimbabwe. This approach 
was also acceptable to the women and there was good 
adherence to the programmatic requirements for follow-up 
and abstinence. The treatment outcomes one year later were 
favourable, with an overall VIAC-positive test rate of only 
2.6%. Policymakers in this and similar low- resource settings 
TABLE 2: Selected clinical and programmatic outcomes.
Variable N %
Screening (N = 4641)
VIA test positive 501 10.8
Satisfied with their decision to be tested 4641 100.0
Cryotherapy (N = 85)
Accepted immediate offer of cryotherapy 84 98.8
Total cryotherapy performed amongst those eligible 84 98.8
Treatments postponed due to staff- or facility-related issues 0 0.0
Delayed treatment due to patient 1 1.9
Clinic visit for perceived problem 0 0.0
Major complications (bleeding, shock, hospitalisation) 0 0.0
Satisfied with their decision to be treated 84 97.7
Complied with post-cryotherapy instructions 82 97.7
Attended follow-up after one year 85 100.0
Tested positive at one year 1 1.2
LEEP (N = 221)
Accepted immediate offer of LEEP 221 100.0
Total LEEP performed amongst those eligible 221 100.0
Treatments postponed due to staff- or facility-related issues 0 0.0
Delayed treatment due to patient 0 0.0
Clinic visit for perceived problem 0 0.0
Major complications (bleeding, shock, hospitalisation) 1 0.5
Satisfied with their decision to be treated 218 98.6
Complied with post-LEEP instructions 218 98.6
Attended follow-up after one year 213 96.4
Tested positive at one year 7/213 3.2
VIAC, visual inspection with acetic acid and cervicograph; LEEP, loop electrical excision 
procedure. 
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should consider prevention programmes for cervical cancer 
based on this approach, rather than adopting models from 
more developed countries.
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